Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Eastern Cooperative Oncology Group
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )
ClinicalTrials.gov Identifier:
NCT02352883
First received: January 16, 2015
Last updated: September 22, 2015
Last verified: September 2015
  Purpose
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.

Condition Intervention
Ductal Breast Carcinoma In Situ
Procedure: Magnetic Resonance Imaging
Procedure: Therapeutic Conventional Surgery
Procedure: Therapeutic Surgical Procedure
Radiation: Radiation Therapy
Drug: Endocrine Therapy
Other: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis
Other: Cytology Specimen Collection Procedure

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Resource links provided by NLM:


Further study details as provided by Eastern Cooperative Oncology Group:

Primary Outcome Measures:
  • Proportion of patients judged to be breast conservation candidates based upon standard imaging and physical examination who convert to mastectomy in step 1 based on MRI findings [ Time Frame: After MRI (within 30 days following study entry), and prior to surgery ] [ Designated as safety issue: No ]
  • Proportion of patients judged to be breast conservation candidates based upon standard imaging and physical examination who have a mastectomy as the final surgical procedure in step 2 [ Time Frame: Up to 12 months post-op ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Factors associated with DCIS score [ Time Frame: After surgery (DCIS Score is determined from surgical specimen) ] [ Designated as safety issue: No ]
    The relation between baseline clinical covariates (tumor grade, necrosis, histologic type, mammographic lesion size), MRI morphologic and kinetic features, and the DCIS score will be assessed.

  • Diagnostic accuracy of MRI in extent of disease evaluation in patients with DCIS [ Time Frame: Up to 12 months post-op ] [ Designated as safety issue: No ]
  • Proportion of patients who require re-operation because of inadequate excision after MRI [ Time Frame: Up to 12 months post-op ] [ Designated as safety issue: No ]
    A two-sided 95% Wilson confidence interval will be derived.

  • Proportion of patients who proceed to mastectomy after an initial attempt at wide local excision because of either inadequate tumor-free margins (< 2mm), or other reasons [ Time Frame: Up to 12 months post-op ] [ Designated as safety issue: No ]
    A two-sided 95% Wilson confidence interval will be derived. In addition to the overall probability of conversion in this cohort, estimates will be stratified by the reason for conversion.

  • IBE rate [ Time Frame: At 5 years ] [ Designated as safety issue: No ]
    Kaplan-Meier curves will be derived for the time to ipsilateral breast event for patients assigned to be treated with RT and those not treated with RT. Point estimates and 95% two-sided confidence intervals will be developed.

  • IBE rate [ Time Frame: At 10 years ] [ Designated as safety issue: No ]
    Kaplan-Meier curves will be derived for the time to ipsilateral breast event for patients assigned to be treated with RT and those not treated with RT. Point estimates and 95% two-sided confidence intervals will be developed.

  • Proportion of women who receive treatment that is concordant with their treatment goals and concerns [ Time Frame: Up to 24 months post-op ] [ Designated as safety issue: No ]
    The proportion of patients with concordant care will be calculated and a 95% Wilson confidence interval will also be derived.

  • Proportion of women whose decision autonomy preference was concordant with perceived level of decision involvement [ Time Frame: Up to 5 days after pre-surgical consultation ] [ Designated as safety issue: No ]
    Concordance will be defined as an exact match between decision autonomy preference (patient-based, shared, surgeon-based) and perceived level of decision involvement (patient based, shared, surgeon-based) as assessed by the Control Preferences Scale, reduced to three categories. The proportion of patients with concordance will be calculated for the sample. In addition, the degree of concordance over the group will be determined using kappa analysis.

  • Decision quality, assessed using the composite of knowledge score and decision process score [ Time Frame: Up to 5 days after pre-surgical consultation ] [ Designated as safety issue: No ]
    To calculate knowledge score, a point for each correct answer on the knowledge questionnaire will be assigned, with missing responses receiving 0 points. A total score will be calculated for all patients who complete at least half of the items and scaled from 0-100%. To calculate a decision process score, a point will be assigned for each "yes" or "a lot/some" response. The sum will be scaled from 0-100%. The average of the two scores will be used as the outcome measure.

  • Role of concordance between decision autonomy preference and perceived level of decision involvement, knowledge and decision process scores as independent predictors of decision satisfaction [ Time Frame: Assessed via questionnaire administered at first post-operative visit ] [ Designated as safety issue: No ]
    Linear regression modeling will be used in which the response variable will be decision satisfaction. The independent variables will be the indicator of concordance between decision autonomy preference and perceived level of decision involvement, the knowledge score and the decision process score. Two-way interactions between predictors will also be examined.

  • Patient-reported quality of life, measured using the Patient Reported Outcomes Measurement Information System (PROMIS)10 instrument [ Time Frame: At 12 months post-op ] [ Designated as safety issue: No ]
    The relationship of patient-reported outcomes and disease specific covariates, and quality of life will be assessed.

  • Patient-reported quality of life, measured using the PROMIS10 instrument [ Time Frame: At 24 months post-op ] [ Designated as safety issue: No ]
    The relationship of patient-reported outcomes and disease specific covariates, and quality of life will be assessed.

  • Role of disease status, diagnostic test results, and surgeon recommendation as predictors of treatment received [ Time Frame: Up to 24 months post-op ] [ Designated as safety issue: No ]
    Logistic regression modeling will be used in which the response variable will be the indicator of conversion to mastectomy (vs lumpectomy). The independent variables will include covariates describing disease status at baseline, MRI results, surgeon recommendation, patient decision involvement (such as the decision autonomy preference scale) and treatment concerns (as measured via the 7-item questionnaire). Separate analyses will be performed for conversion to mastectomy directly post MRI and conversion to mastectomy following BCS as the response variable.

  • Patient-reported diagnostic testing burden of bilateral mammogram, MRI, and biopsies, measured by TMI [ Time Frame: Up to 5 days after pre-surgical consultation ] [ Designated as safety issue: No ]
    A Wilcoxon signed rank test will be used to compare TMI scores for mammography and MRI. In a secondary analysis regression modeling will be used to examine the effects of patient characteristics on the patient's perception of diagnostic test burden for the two modalities.


Estimated Enrollment: 350
Study Start Date: March 2015
Estimated Primary Completion Date: November 2027 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (MRI)
Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
  • Magnetic Resonance Imaging Scan
  • MRI
  • MRI Scan
  • NMRI
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Cytology Specimen Collection Procedure
Correlative studies
Other Name: Cytologic Sampling
Experimental: Arm B (mastectomy)
Patients undergo a mastectomy. Patients do not register for Step 3.
Procedure: Therapeutic Conventional Surgery
Undergo mastectomy
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Cytology Specimen Collection Procedure
Correlative studies
Other Name: Cytologic Sampling
Experimental: Arm C (wide local excision)
Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
Procedure: Therapeutic Surgical Procedure
Undergo wide local excision
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Cytology Specimen Collection Procedure
Correlative studies
Other Name: Cytologic Sampling
Experimental: Arm D (endocrine therapy)
Patients undergo endocrine therapy as directed.
Drug: Endocrine Therapy
Undergo endocrine therapy
Other Names:
  • Chemotherapy-Hormones/Steroids
  • Hormonal Therapy
  • Hormone Therapy
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Cytology Specimen Collection Procedure
Correlative studies
Other Name: Cytologic Sampling
Experimental: Arm E (radiation therapy, endocrine therapy)
Patients undergo radiation therapy and endocrine therapy as directed.
Radiation: Radiation Therapy
Undergo radiation therapy
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • Irradiation
  • RT
Drug: Endocrine Therapy
Undergo endocrine therapy
Other Names:
  • Chemotherapy-Hormones/Steroids
  • Hormonal Therapy
  • Hormone Therapy
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Laboratory Biomarker Analysis
Correlative studies

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Registration to Step 1:
  • Patients must have pathologically confirmed diagnosis of unilateral ductal carcinoma in situ with no evidence of microinvasive or invasive disease obtained by core needle biopsy within 4 months of registration; patients diagnosed by surgical excision are not eligible; patients with synchronous bilateral disease are not eligible; patients with synchronous bilateral disease (i.e., synchronous DCIS or invasive cancer) are not eligible

    • Patients will be staged prior to registration according to the clinical staging criteria adapted from the American Joint Committee on Cancer (AJCC) Cancer Staging Data Forms of the AJCC Cancer Staging Manual, 7th Edition, 2009; Note: For consistency purposes, AJCC 7th Edition will continue to be used throughout the entire study enrollment period
  • Required studies include a bilateral screening mammogram within 6 months and diagnostic mammogram of the affected breast within 3 months prior to registration
  • Patients must not have previous ipsilateral invasive breast cancer or DCIS
  • Patients must not have known deleterious mutations in breast cancer (BRCA) genes
  • Patients must not have received hormonal therapy (i.e., tamoxifen, raloxifene, and/or aromatase inhibitors) for prevention of breast cancer within 3 months of the biopsy documenting DCIS
  • Patients must not have history of chemotherapy for cancer within 6 months prior to registration
  • No prior history of breast radiotherapy that will prevent the use of radiotherapy for the present DCIS
  • Patients must be judged to be suitable to undergo MRI and receive the contrast agent gadolinium (exclusions follow):

    • No history of untreatable claustrophobia;
    • No presence of metallic objects or implanted medical devices in body (i.e., cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants);
    • No history of sickle cell disease;
    • No contraindication to intravenous contrast administration;
    • No known allergy-like reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR); patient may be eligible if willing to undergo pre-treatment as defined by the institution's policy and/or ACR guidance;
    • No findings consistent with renal failure, as determined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2 based on a serum creatinine level obtained within 28 days prior to registration;
    • Weight lower than that allowable by the MRI table;
  • No prior MRI of the breasts within the 6 months prior to registration
  • Patients must be eligible for breast-conserving therapy (BCT) based on clinical examination and mammography; if ultrasound is performed, findings must also be consistent with eligibility for BCT
  • Patients must not have multicentric disease scheduled to undergo multiple lumpectomies; multifocal disease that can be encompassed in a single operative bed are eligible
  • Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 3 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study
  • Registration to Step 2:
  • MRI has been performed in Step 1, and additional imaging studies and biopsies performed if indicated
  • The clinician/patient has made the decision as to whether the patient will proceed to wide local excision or mastectomy
  • Registration to Step 3:
  • Patient's most recent surgery was wide local excision with or without re-excision and for which there was obtained clear (>= 2 mm) margins at breast conserving surgery, and the pathology reveals pure DCIS; patients with invasive cancer or DCIS with microinvasion will not be registered on step 3, but will be followed for clinical outcomes
  • The OncotypeDX Patient Report of the DCIS Score from the OncotypeDX Breast Cancer Assay performed by Genomic Health on the excision tissue have been uploaded by the site into the Rave electronic case report forms (eCRF)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02352883

  Show 76 Study Locations
Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Investigators
Principal Investigator: Constance Lehman ECOG-ACRIN Cancer Research Group
  More Information

Responsible Party: ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT02352883     History of Changes
Other Study ID Numbers: E4112  NCI-2014-01261  E4112  ECOG-E4112  UG1CA189828  U10CA037403 
Study First Received: January 16, 2015
Last Updated: September 22, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma
Breast Neoplasms
Carcinoma in Situ
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Carcinoma, Ductal
Adenocarcinoma
Neoplasms, Ductal, Lobular, and Medullary
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on December 09, 2016